FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports

The U.S. Food and Drug Administration has selected Eli Lilly NYSE:LLY and Regeneron NASDAQ:REGN, among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC reported on Monday citing an FDA spokesperson.